Literature DB >> 15580480

A population-based study of osteoporosis testing and treatment following introduction of a new bone densitometry service.

William D Leslie1, Leonard MacWilliam, Lisa Lix, Patricia Caetano, Gregory S Finlayson.   

Abstract

Bone density measurement plays a key role in the initial diagnostic assessment of osteoporosis and in targeting pharmacologic therapies. The impact of access to dual-energy X-ray absorptiometry (DXA) on physician prescribing habits is unclear, however. We were able to directly evaluate the change in physician osteoporosis testing and prescribing following introduction of a DXA testing service in a geographic region that had previously had very limited access. This evaluation was conducted in the province of Manitoba, Canada, which has a provincially based bone density testing program and maintains a population-based bone density database that can be linked with administrative health data sources including drug prescriptions. The province of Manitoba was geographically partitioned into the urban and rural health regions serviced by the new program (urban(new )and rural(new)) and the remaining urban and rural health regions which had relatively unchanged DXA access during this period (urban(control) and rural(control)). Regression models of DXA testing rates and osteoporosis prescription rates were created for all older women in these regions. There was a statistically significant increase in bone density testing and BMD-guided osteoporosis treatment in the urban(new) and rural(new) regions following introduction of the DXA testing service, relative to the control regions. Although the overall rate of empiric postfracture and preventive osteoporosis treatment did not show a specific region effect, when analysis was limited to nonhormonal agents there was a significant reduction in preventive and empiric postfracture treatment in some subgroups of women. These results suggest that the local availability of the bone density testing service led to an increase in objective test-guided therapy with some reduction in the use of empiric and preventive strategies and had a neutral effect on overall use of these agents.

Entities:  

Mesh:

Year:  2004        PMID: 15580480     DOI: 10.1007/s00198-004-1756-5

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  19 in total

1.  The population's use of pharmaceuticals.

Authors:  C Metge; C Black; S Peterson; A L Kozyrskyj
Journal:  Med Care       Date:  1999-06       Impact factor: 2.983

2.  Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system.

Authors:  N P Roos; E Shapiro
Journal:  Med Care       Date:  1999-06       Impact factor: 2.983

3.  Assessing data quality: a computerized approach.

Authors:  L L Roos; S M Sharp; A Wajda
Journal:  Soc Sci Med       Date:  1989       Impact factor: 4.634

4.  Short-term mortality after repair of hip fracture. Do Manitoba elderly do worse?

Authors:  L L Roos; R K Walld; P S Romano; S Roberecki
Journal:  Med Care       Date:  1996-04       Impact factor: 2.983

5.  What is the impact of osteoporosis education and bone mineral density testing for postmenopausal women in a managed care setting?

Authors:  S J Rolnick; R Kopher; J Jackson; L R Fischer; R Compo
Journal:  Menopause       Date:  2001       Impact factor: 2.953

6.  Evaluation of osteoporosis treatment in seniors after hip fracture.

Authors:  A G Juby; C M De Geus-Wenceslau
Journal:  Osteoporos Int       Date:  2002-03       Impact factor: 4.507

7.  Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation.

Authors:  Adrianne Feldstein; Patricia J Elmer; Eric Orwoll; Michael Herson; Teresa Hillier
Journal:  Arch Intern Med       Date:  2003-10-13

8.  Older women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatment.

Authors:  Adrianne C Feldstein; Gregory A Nichols; Patricia J Elmer; David H Smith; Mikel Aickin; Michael Herson
Journal:  J Bone Joint Surg Am       Date:  2003-12       Impact factor: 5.284

9.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

10.  Establishing a regional bone density program: lessons from the Manitoba experience.

Authors:  William D Leslie; Colleen Metge
Journal:  J Clin Densitom       Date:  2003       Impact factor: 2.963

View more
  14 in total

1.  A comparative study of using non-hip bone density inputs with FRAX®.

Authors:  W D Leslie; L M Lix; H Johansson; A Oden; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2011-10-19       Impact factor: 4.507

2.  Competing mortality and fracture risk assessment.

Authors:  W D Leslie; L M Lix; X Wu
Journal:  Osteoporos Int       Date:  2012-06-27       Impact factor: 4.507

3.  Osteoporosis onset differences between rural and metropolitan populations: correlation to fracture type, severity, and treatment efficacy.

Authors:  Thomas Pagonis; Panagiotis Givissis; Athanasios Pagonis; Georgios Petsatodis; Anastasios Christodoulou
Journal:  J Bone Miner Metab       Date:  2011-06-14       Impact factor: 2.626

4.  High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice.

Authors:  W D Leslie; S R Majumdar; L M Lix; H Johansson; A Oden; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2011-03-02       Impact factor: 4.507

5.  FRAX for fracture prediction shorter and longer than 10 years: the Manitoba BMD registry.

Authors:  W D Leslie; S R Majumdar; S N Morin; L M Lix; H Johansson; A Oden; E V McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2017-06-07       Impact factor: 4.507

6.  Fracture risk assessment without bone density measurement in routine clinical practice.

Authors:  W D Leslie; S Morin; L M Lix; H Johansson; A Oden; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2011-08-18       Impact factor: 4.507

7.  Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment.

Authors:  W D Leslie; L M Lix; L Langsetmo; C Berger; D Goltzman; D A Hanley; J D Adachi; H Johansson; A Oden; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2010-12-16       Impact factor: 4.507

8.  Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts.

Authors:  W D Leslie; C Berger; L Langsetmo; L M Lix; J D Adachi; D A Hanley; G Ioannidis; R G Josse; C S Kovacs; T Towheed; S Kaiser; W P Olszynski; J C Prior; S Jamal; N Kreiger; D Goltzman
Journal:  Osteoporos Int       Date:  2010-10-22       Impact factor: 4.507

9.  Prediction of hip and other osteoporotic fractures from hip geometry in a large clinical cohort.

Authors:  W D Leslie; P S Pahlavan; J F Tsang; L M Lix
Journal:  Osteoporos Int       Date:  2009-02-24       Impact factor: 4.507

10.  Utility of heel dual-energy X-ray absorptiometry in diagnosing osteoporosis.

Authors:  Sharon H Chou; Jessica Hwang; Siu-Ling Ma; Tamara Vokes
Journal:  J Clin Densitom       Date:  2013-10-19       Impact factor: 2.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.